Details from the source.
This catalogue entry records Thymalin, 10 mg × 10 vials (SKU TY10), using the supplied source listing. The cited dossier describes: Research has addressed immune modulation and lymphocyte measures, infections, immune suppression and blood-cell recovery, and aging-related changes. Translational findings and human reports are limited; the findings should not be presented as established product effects. It also distinguishes available human evidence, limitations, safety concerns, and regulatory context. It does not verify this supplier-specific item’s identity, formulation, lot quality, or approval. This is not medical advice, a treatment recommendation, or authorization for human use.
- Catalogue code
- TY10
- Source specification
- 10mg*10vials
- Source document
- PriceList(1).pdf, page 3
- Photograph
- Owner-supplied photograph; visible package label matched to this catalogue entry. Supplier identity, lot, and product quality have not been independently verified.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
In the scientific literature, Thymalin is described as a thymus-derived polypeptide complex containing multiple short peptides—not a single chemically defined peptide. The catalogue identifies TY10 as ‘Thymalin’, but its exact source, composition, or identity is not verified. Source-only listing: *10vials; 63 per 10 vials; currency unstated.
Biological mechanism
Proposed mechanisms in the literature include short peptides influencing gene expression and proteins involved in immune-cell differentiation, proliferation, apoptosis, cytokine signaling, and hemostasis, possibly through binding DNA or histone proteins. These proposals are not established for the catalogue vial. [1]
Research focus
Research has addressed immune modulation and lymphocyte measures, infections, immune suppression and blood-cell recovery, and aging-related changes. Translational findings and human reports are limited; the findings should not be presented as established product effects. [1][2][3]
Potential applications in the evidence
Investigated contexts include immune dysfunction and severe infection, including a small study in older patients with severe COVID-19, as well as aging-related outcomes and immune or blood-cell recovery. These are research topics, not proven uses or efficacy claims. Some older findings involved Thymalin together with Epithalamin and cannot establish standalone Thymalin effects. [2][3]
Human evidence
One published, single-center, single-blind randomized study included 80 older adults hospitalized with severe COVID-19 and reported group differences in clinical improvement and in-hospital mortality. Its small size, specific setting, 2020-era standard care, and lack of independent replication limit what it establishes; it does not establish outcomes for TY10. [2] A PubMed-indexed report assessed Thymalin and Epithalamin in older people over several years, but its abstract provides limited methodological detail and includes combination-treatment findings, which cannot be attributed to Thymalin alone. [3] ClinicalTrials.gov showed no records for the exact ‘Thymalin’ search at review time; this is not proof that no human research exists. [4]
Known and potential effects
A reliable adverse-effect profile and incidence have not been established. A broad statement in the COVID-19 paper that no side effects occurred is not supported there by a detailed adverse-event analysis and is not evidence of safety. [2] Hypersensitivity or risks related to impurities or contamination are plausible concerns for an animal-tissue-derived preparation, but are not confirmed event rates for TY10.
Safety and contraindications
The exact vial's identity, source material, composition, purity, potency, sterility, and contaminant testing are unknown from the supplied information. No product-specific contraindications or interaction profile can be verified. A study's exclusion criteria are not established contraindications. Do not imply safety or suitability for human use.
U.S. FDA / regulatory status
No FDA-approved Thymalin formulation was identified in this review. In a 2024 warning letter, FDA stated that a different company's marketed Thymalin product was an unapproved new drug and that no approved applications were in effect for that company's products. That finding applies to that firm's product and is not a determination about TY10. The catalogue does not identify a manufacturer, lot, formulation source, or jurisdiction, so FDA status for the exact vial cannot be verified and approval of any other formulation cannot be transferred to it. [5][6]
Evidence limitations
The listing's exact product identity and composition are undocumented. Available human studies are few, small or methodologically unclear, and not independently replicated sufficiently to establish efficacy or safety. Evidence about a described research or medicinal preparation cannot be presumed to apply to TY10. No combination evidence should be transferred from Thymalin-plus-Epithalamin reports to Thymalin alone.
Supporting sources
- The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity Biology Bulletin Reviews / PubMed Central · Peer-reviewed review. Supports: Literature description as a thymus-derived polypeptide complex, proposed molecular mechanisms, and reviewed research focus.
- Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Patients Biology Bulletin Reviews / PubMed Central · Peer-reviewed primary human study. Supports: Design and reported results of the small randomized severe-COVID-19 study, and limits of its adverse-effect reporting.
- Geroprotective effect of thymalin and epithalamin PubMed, National Library of Medicine · PubMed-indexed review with English abstract of human clinical assessment. Supports: Reported long-term human assessment and combination-treatment findings, with the limits evident from the abstract.
- ClinicalTrials.gov search for Thymalin ClinicalTrials.gov, National Library of Medicine · Official clinical trial registry search. Supports: Exact-name registry search showed no records at review time; a search result is not proof that no human research exists.
- US Chem Labs MARCS-CMS 669074 — February 07, 2024 U.S. Food and Drug Administration · FDA warning letter. Supports: FDA's unapproved-new-drug finding for the addressed company's Thymalin product; not a finding about the catalogue vial.
- Drug Approvals and Databases U.S. Food and Drug Administration · Official FDA database directory. Supports: FDA's official directory of drug-approval databases; relevant context for approval searches, not proof of this vial's status.